Product Overview

Glibenclamide 2.5 mg is a generic oral antidiabetic medication manufactured by Sanofi India Limited. It belongs to the sulfonylurea class of drugs and is specifically indicated for the management of type 2 diabetes mellitus. Each strip contains ten film‑coated tablets, each delivering a precise 2.5 mg dose of glibenclamide. The product is packaged in multiple pack sizes – 60, 90, or 120 tablets – to accommodate varying treatment durations. Delivery typically occurs within six to fifteen days after order placement, making it a convenient option for patients seeking reliable glycemic control. This medication is available through authorized online pharmacies that comply with national regulatory standards, ensuring authenticity and proper storage conditions.

What is Glibenclamide 2.5 mg (Generic)

Glibenclamide, also known as glipizide in some regions, is a second‑generation sulfonylurea that lowers blood glucose by stimulating pancreatic beta‑cells to release insulin. The 2.5 mg strength is the most commonly prescribed dose for initiation in adult patients with type 2 diabetes who have not achieved adequate control through diet and exercise alone. As a generic formulation, it contains the same active ingredient and meets the same quality specifications as the reference brand, offering a cost‑effective alternative without compromising efficacy. The tablets are scored and can be split if clinically appropriate, allowing flexibility in dose adjustment. For more detailed pharmacologic information, refer to authoritative sources such as the National Institutes of Health (https://www.nih.gov) or the U.S. Food and Drug Administration (https://www.fda.gov).

Uses and Benefits

The primary use of glibenclamide 2.5 mg is to improve glycemic control in adults with type 2 diabetes mellitus, particularly when lifestyle modifications are insufficient. By increasing insulin secretion, the drug helps reduce fasting and post‑prandial glucose levels, thereby decreasing the risk of long‑term complications such as neuropathy, retinopathy, and cardiovascular disease. Clinically, patients often experience a measurable decline in HbA1c percentages after several weeks of consistent therapy. The medication is also beneficial for patients who require an oral agent that does not cause weight gain as prominently as some other oral hypoglycemics. Its once‑daily dosing simplifies regimen adherence, and the availability of multiple pack sizes supports flexible supply chain management for both patients and caregivers.

How It Works

Glibenclamide exerts its hypoglycemic effect by binding to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta‑cells. This interaction leads to closure of ATP‑sensitive potassium channels, depolarization of the cell membrane, and subsequent influx of calcium ions. The resulting cascade triggers the exocytosis of stored insulin granules into the bloodstream. Because the drug enhances endogenous insulin release, its action is glucose‑dependent; it is less likely to cause hypoglycemia when blood glucose levels are low. In addition, glibenclamide may modestly improve insulin sensitivity in peripheral tissues, contributing to overall glycemic stability. The pharmacokinetic profile features a rapid onset of action within one to two hours and a duration of effect lasting approximately 12 to 16 hours, which supports once‑daily administration.

Dosage Guidelines

Initial therapy typically begins with one 2.5 mg tablet taken orally once daily, preferably with breakfast to reduce the risk of gastrointestinal discomfort. Depending on the patient’s response and tolerability, the dose may be titrated upward in increments of 2.5 mg at intervals of four to six weeks, aiming for a maximum daily dose of 10 mg (four tablets). It is essential to monitor blood glucose concentrations regularly, especially after dose adjustments, to avoid excessive lowering of glucose levels. Patients with renal impairment or those over the age of 65 should start at the lowest dose and be closely observed. Always follow the prescribing information or the guidance of a qualified healthcare professional, and do not exceed the recommended daily amount.

Side Effects

Like all medications, glibenclamide 2.5 mg can produce adverse effects, although many are mild and transient. Common side effects include hypoglycemia, dizziness, headache, and mild gastrointestinal symptoms such as nausea or abdominal discomfort. Less frequent but clinically important reactions comprise skin rashes, pruritus, and, rarely, severe hypersensitivity reactions requiring immediate medical attention. In rare cases, hepatic enzyme elevations have been reported; therefore, liver function tests may be advisable for patients with pre‑existing liver disease. If any sign of severe hypoglycemia (e.g., confusion, seizures, loss of consciousness) occurs, prompt glucose administration and emergency medical care are warranted. For a comprehensive list of side effects, consult the medication’s package insert or a healthcare provider.

Warnings and Precautions

Before initiating treatment with glibenclamide, healthcare professionals should assess renal function, hepatic health, and cardiovascular status, as these factors can influence dosing requirements and safety. The drug is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a history of severe hypoglycemia. Caution is advised in individuals with adrenal or pituitary insufficiency, as well as those undergoing surgery or diagnostic procedures that may affect glucose regulation. Concomitant use of certain medications – such as certain antibiotics, antifungals, or beta‑blockers – may potentiate hypoglycemic risk and necessitate dose modification. Pregnant or breastfeeding women should only use glibenclamide if the anticipated benefit justifies potential risks, and they must discuss this with their physician. Store the tablets in a dry place, protected from excessive heat and moisture.

Frequently Asked Questions

1. Can glibenclamide be taken with other diabetes medications? Yes, it can be combined with metformin or other oral agents, but dosage adjustments are often required to prevent hypoglycemia. Always coordinate with a healthcare professional.
2. How long does it take to see a reduction in blood sugar levels? Most patients notice a measurable decline in fasting glucose within one to two weeks of consistent dosing, with maximal effect observed after four to six weeks.
3. Is the 2.5 mg strength suitable for elderly patients? Elderly individuals often start at a lower dose due to increased sensitivity and may need slower titration; medical supervision is essential.
4. What should I do if I miss a dose? Take the missed tablet as soon as you remember, unless it is almost time for the next scheduled dose; then skip the missed dose and resume the regular schedule.
5. Are there any dietary restrictions while using glibenclamide? No specific diet is required, but maintaining a balanced carbohydrate intake and regular meal timing helps stabilize blood glucose and reduces the risk of hypoglycemia.

Related Products

• Allegra (Fexofenadine)
• Fexofenadine 30 Mg (Generic)
• Fexofenadine 120 Mg (Generic)
• Fexofenadine 180 Mg (Generic)
• Allegra 120 mg (Fexofenadine)
• Allegra 30mg (Fexofenadine)
• Allegra Nasal Duo Spray (Fluticasone / Azelastine)
• Allegra 180 mg (Fexofenadine)
• Okamet 500 Mg (Metformin)
• Framycetin Sulphate Cream (Generic)
• Teicoplanin 400mg (Generic)
• Soframycin Cream (Framycetin Sulphate)